Phase I dose-ascending trial of Pharmacokinetics and Tolerability of single, High Doses of USL255, an Extended-Release Topiramate Formulation in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 23 May 2014
At a glance
- Drugs Topiramate (Primary)
- Indications Epilepsy
- Focus Adverse reactions; Pharmacokinetics
- 15 Oct 2013 Results presented at the American Neurological Association's 2013 Annual Meeting.
- 24 Jun 2013 Results will be presented at the 30th International Epilepsy Congress (IEC) in 2013.
- 10 Dec 2012 New trial record